Risk Factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients : A Multinational Case-Control Study
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Risk factors for nontuberculous mycobacteria (NTM) infections after solid organ transplant (SOT) are not well characterized. Here we aimed to describe these factors.
METHODS: Retrospective, multinational, 1:2 matched case-control study that included SOT recipients ≥12 years old diagnosed with NTM infection from 1 January 2008 to 31 December 2018. Controls were matched on transplanted organ, NTM treatment center, and post-transplant survival greater than or equal to the time to NTM diagnosis. Logistic regression on matched pairs was used to assess associations between risk factors and NTM infections.
RESULTS: Analyses included 85 cases and 169 controls (59% male, 88% White, median age at time of SOT of 54 years [interquartile range {IQR} 40-62]). NTM infection occurred in kidney (42%), lung (35%), heart and liver (11% each), and pancreas transplant recipients (1%). Median time from transplant to infection was 21.6 months (IQR 5.3-55.2). Most underlying comorbidities were evenly distributed between groups; however, cases were older at the time of NTM diagnosis, more frequently on systemic corticosteroids and had a lower lymphocyte count (all P < .05). In the multivariable model, older age at transplant (adjusted odds ratio [aOR] 1.04; 95 confidence interval [CI], 1.01-1.07), hospital admission within 90 days (aOR, 3.14; 95% CI, 1.41-6.98), receipt of antifungals (aOR, 5.35; 95% CI, 1.7-16.91), and lymphocyte-specific antibodies (aOR, 7.73; 95% CI, 1.07-56.14), were associated with NTM infection.
CONCLUSIONS: Risk of NTM infection in SOT recipients was associated with older age at SOT, prior hospital admission, receipt of antifungals or lymphocyte-specific antibodies. NTM infection should be considered in SOT patients with these risk factors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e995-e1003 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 10.02.2023 Date Revised 20.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac608 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343993260 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343993260 | ||
| 003 | DE-627 | ||
| 005 | 20231226021733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac608 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343993260 | ||
| 035 | |a (NLM)35879465 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mejia-Chew, Carlos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk Factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients |b A Multinational Case-Control Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2023 | ||
| 500 | |a Date Revised 20.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Risk factors for nontuberculous mycobacteria (NTM) infections after solid organ transplant (SOT) are not well characterized. Here we aimed to describe these factors | ||
| 520 | |a METHODS: Retrospective, multinational, 1:2 matched case-control study that included SOT recipients ≥12 years old diagnosed with NTM infection from 1 January 2008 to 31 December 2018. Controls were matched on transplanted organ, NTM treatment center, and post-transplant survival greater than or equal to the time to NTM diagnosis. Logistic regression on matched pairs was used to assess associations between risk factors and NTM infections | ||
| 520 | |a RESULTS: Analyses included 85 cases and 169 controls (59% male, 88% White, median age at time of SOT of 54 years [interquartile range {IQR} 40-62]). NTM infection occurred in kidney (42%), lung (35%), heart and liver (11% each), and pancreas transplant recipients (1%). Median time from transplant to infection was 21.6 months (IQR 5.3-55.2). Most underlying comorbidities were evenly distributed between groups; however, cases were older at the time of NTM diagnosis, more frequently on systemic corticosteroids and had a lower lymphocyte count (all P < .05). In the multivariable model, older age at transplant (adjusted odds ratio [aOR] 1.04; 95 confidence interval [CI], 1.01-1.07), hospital admission within 90 days (aOR, 3.14; 95% CI, 1.41-6.98), receipt of antifungals (aOR, 5.35; 95% CI, 1.7-16.91), and lymphocyte-specific antibodies (aOR, 7.73; 95% CI, 1.07-56.14), were associated with NTM infection | ||
| 520 | |a CONCLUSIONS: Risk of NTM infection in SOT recipients was associated with older age at SOT, prior hospital admission, receipt of antifungals or lymphocyte-specific antibodies. NTM infection should be considered in SOT patients with these risk factors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a NTM | |
| 650 | 4 | |a nontuberculous mycobacteria | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a solid organ transplant | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Carver, Peggy L |e verfasserin |4 aut | |
| 700 | 1 | |a Rutjanawech, Sasinuch |e verfasserin |4 aut | |
| 700 | 1 | |a Camargo, Luis F Aranha |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Ruan |e verfasserin |4 aut | |
| 700 | 1 | |a Belga, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Daniels, Shay-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Nicolas J |e verfasserin |4 aut | |
| 700 | 1 | |a Burkhard, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Theodoropoulos, Nicole M |e verfasserin |4 aut | |
| 700 | 1 | |a Postma, Douwe F |e verfasserin |4 aut | |
| 700 | 1 | |a van Duijn, Pleun J |e verfasserin |4 aut | |
| 700 | 1 | |a Fariñas, María Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a González-Rico, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Hand, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Lowe, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Bodro, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Vanino, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, Ana Fernández |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Makek, Mateja Jankovic |e verfasserin |4 aut | |
| 700 | 1 | |a Mjahed, Ribal Bou |e verfasserin |4 aut | |
| 700 | 1 | |a Manuel, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Kamar, Nassim |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo-Cano, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco, Laura Rueda |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Recio, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Sabé, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez, Regino Rodríguez |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, José Tiago |e verfasserin |4 aut | |
| 700 | 1 | |a Mularoni, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Titos, Juana |e verfasserin |4 aut | |
| 700 | 1 | |a Del Rosal, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Classen, Annika Y |e verfasserin |4 aut | |
| 700 | 1 | |a Goss, Charles W |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Mansi |e verfasserin |4 aut | |
| 700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e995-e1003 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e995-e1003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac608 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e995-e1003 | ||